Tue, Sep 16, 2014, 12:18 PM EDT - U.S. Markets close in 3 hrs 42 mins

Recent

% | $
Quotes you view appear here for quick access.

Pfizer Inc. Message Board

  • bubblyjoe51 bubblyjoe51 Feb 11, 2011 9:03 AM Flag

    JP Morgan rates Pfizer 25.00$

    Chartness has been overly conservative relative to Pfizer's share price down the road. JPMorgan now rates Pfizer a 25.00$ stock.

    All indications point to Shamelessjackass leaving the board soon. Good riddance.

    Keep up the good work Chartness with your accurate predictions.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Not to mention his accurate calculations on compound gains or in his case, compound losses.

      Next time "think before you post"

      Imagine me, a simple buy and hold investor just plodding along, ripping the great options trading genius.

      Run along and play, now.

    • This is one giant of a company and they are loaded with cash. wait till they get done with their streamlining of mergers, solidifying of R&D, roll out new products and as we see analysts are just beginning to wake up to Pfizers true wealth. I personally own thousands of shares and am excited going forward. Read my last post from the street....

    • Thanks, Ruffturd, for yet again giving the betters an opportunity to remind everyone of Alan's hilarious record of always being wildly wrong, & promptly shown so, often within an hour, as with the dozen "obvious, absolute bottoms" the fool called last year.

    • > Keep up the good work Chartness with your accurate predictions.




      =============================================
      Re: My ship will be coming in 31-Oct-07 07:12 pm

      Here is an excerpt from your post:


      Risk management is absolutely critical to succeed in the market.



      The biggest part of risk management is to put yourself in situations that simply aren't very risky. Pfizer at these prices is virtually riskless. That's what I call managing risk extremely well.

      chrt13
      ===================================================


      chrt13 said " Pfizer at these prices is virtually riskless."

      And what are "these prices?"

      Well, PFE closed at $24.61 the day chrt13 posted the above message.

    • > Chartness has been overly conservative relative to Pfizer's share price down the road.


      ***************************************************
      Summarizing my PFE predictions still in force 1-Mar-07 11:55 am

      I expect the following:

      1) Tuesday's close of $25.14 will prove to be in the lowest 10% of the range between the low close of the year and the high close of the year.

      2) Today's $24.55 intraday low will also be the 2007 intraday low.

      3) $31 will be seen on a closing basis before the year is out.

      4) Pro forma earnings per share this year will be at least $2.30.

      chrt03
      *****************************************************

    • > Keep up the good work Chartness with your accurate predictions.


      ================================================================
      Re: Milo, your bet's looking good! Already 65% of the way 13-Jun-07 08:25 pm

      There's no "traditionally" about it. The past three years it just so happens there were major travesties the second half (adverse Celebrex test in 2004, the yanking of estimates in 2005 and Torcetrapib failure in 2006).

      There's nothing apparent in the way of travesties in 2007. No optimistic forecasts and no huge drugs under development that could fail. Any travesty this year would have to come completely out of the blue. There would be little reason for an investor to expect any such thing.

      You saw the lows this year on March 5 with the $24.70 close. Nothing resembling that will be seen. EVER!

      chrt13
      =====================================

    • Joe, why would you call me chartness? I haven't used that handle since a couple years before your ID was born. I thought you started reading my brilliant work here as a class project? Are you a liar Joe?

    • Stick your tongue ever deeper into your chubby hubby's rectum, Ruffnuts!

      Alan's predictions have always been ludicrously optimistic, as you know, liar.

      Alan's target price remains $31, not $25.

      The loser loon's forecasts were for at least $35 in 2005 & $81 for 2012 ($4.50 minimum EPS X P/E of 18), then lowered every year to $32 in 2006, $31 for 2007, 2008 & 2009 & $29 in 2010.

      Alan has always been disastrously wrong, 30,000 times in a row.

      • 2 Replies to cokeeradicator
      • Contrary to Alan's insane spew, analysts have always been ridiculously optimistic about PFE.

      • Stick your tongue ever deeper into your chubby hubby's rectum, Ruffnuts!

        Alan's predictions have always been ludicrously optimistic, as you know, liar.

        Alan's target price remains $31, not $25.

        Shamelessjackass
        ________________________________________________________

        Chartness' predicted price is 22.00$ for this year and 29.00$ in 2013.

        I should point out that if Chartness wouldn't see so many black swans affecting the market, he'd also have a 25.00$ target price.

        I'm really looking forward to the day where we will not have you around spewing nonsense daily on this board under your copious monikers incessantly rating messages with the intent to give them validity. There seems to be no end to your infantile behavior. It's rather odd that you have to be reminded of this on a daily basis.

        Incidently, your name shamelessjackass is most appropriate. It fits you like a glove. I have to give you an A for choosing such a moniker.

        Sick, sick.

    • > Chartness has been overly conservative relative to Pfizer's share price down the road.


      =====================================
      Re: "That was your one and only chance to get it below $25 this year." 10-Jul-07 11:08 am

      The stock is down by all of a dime right now and even at its worst when the Dow was down 80 it was still $25.68 - still quite a ways from falling below $25.

      For the sake of a few dimes, you are going to miss out on buying shares at a price that doesn't figure to be seen again once earnings come out.

      In the long-term scheme of things, is there really much difference in buying the stock at $25.80 as opposed to say $25.20? With earnings being this close, Pfizer figures to hold on better than you might expect even if the market tumbles.

      Don't be silly and miss out on these . Pull the trigger this week - before earnings start having a positive effect.

      chrt13
      =========================================
      =========================================
      Re: One reason for today's drug industry weakness 9-Jul-07 03:56 pm

      Pfizer was on sale below $25 in early March. That was your one and only chance to get it below $25 this year. You won't be getting that chance again as Q2 earnings are coming out just nine days hence and even the kind of price you are seeing today will no longer be available. The one thing that ALWAYS lights a fire under the stock is when management is obliged to hike full-year estimates. They generally only do it once a year - or twice at best. The Q2 earnings release is far-and-away the most logical time for it to occur - especially after a material Q1 beat when the company has stood pat.

      If you think the company is a buy at $24.80, it's also a buy at $25.90. In the long-term scheme of things, a buck-ten is nothing.

      Don't let a relatively-trivial difference deter you from obtaining shares at a price that you aren't likely to see again.

      You might want to look at what happened to SGP in April. Before then, the stock could have been had in the low-to-mid twenties all day. No more - now it's rarely seen below $30. I see the same kind of scenario for Pfizer starting a week from Wednesday.

      chrt13


      ================================================================

 
PFE
30.045+0.125(+0.42%)12:18 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.